Trazodone Add-on in COVID-19-related Selective Serotonin Reuptake Inhibitor-resistant Post-traumatic Stress Disorder in Healthcare Workers: Two Case Reports
10.9758/cpn.2021.19.4.780
- Author:
Domenico De BERARDIS
1
;
Michele FORNARO
;
Antonio VENTRIGLIO
;
Alessandro VALCHERA
;
Federica VELLANTE
;
Mauro PETTORRUSO
;
Giovanni MARTINOTTI
;
Silvia FRATICELLI
;
Massimo Di GIANNANTONIO
Author Information
1. National Health Service, Department of Mental Health, Psychiatric Service for Diagnosis and Treatment, Hospital “G. Mazzini”, Teramo, Italy
- Publication Type:Case Report
- From:Clinical Psychopharmacology and Neuroscience
2021;19(4):780-785
- CountryRepublic of Korea
- Language:English
-
Abstract:
COVID-19 represents a significant stress factor for all people worldwide due to several factors, including quarantine, lockdowns, fear of contagion, deaths, and other traumatic events. However, the healthcare workers (HCWs) have paid the higher price of this pandemic in terms of fatalities, contagions, and psychological well-being. Studies suggest that this particular population is at increased risk of developing a severe post-traumatic stress disorder (PTSD). The early diagnosis and timely treatment of PTSD in HCWs may restore well-being and significantly impact health services functioning, reducing burnout, days spent far from work, disrupted personal and team empowerment, and worse job performances. In the present article, we reported on two cases of HCWs directly involved in the treatment of COVID-19patients who showed selective serotonin reuptake inhibitor-resistant PTSD, which was successfully treated with extended-release trazodone TRZ ContramidⓇ add-on.
